RT Journal Article
SR Electronic
T1 Cross-talk between red blood cells and plasma influences blood flow and omics phenotypes in severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.31.22273226
DO 10.1101/2022.03.31.22273226
A1 Recktenwald, Steffen M.
A1 Simionato, Greta
A1 Lopez, Marcelle G. M.
A1 Gamboni, Fabia
A1 Dzieciatkowska, Monika
A1 Meybohm, Patrick
A1 Zacharowski, Kai
A1 Knethen, Andreas von
A1 Wagner, Christian
A1 Kaestner, Lars
A1 D’Alessandro, Angelo
A1 Quint, Stephan
YR 2022
UL http://medrxiv.org/content/early/2022/03/31/2022.03.31.22273226.abstract
AB Coronavirus disease 2019 (COVID-19) is caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can affect multiple organs, among which is the circulatory system. Inflammation and mortality risk markers were previously detected in COVID-19 plasma and red blood cells (RBCs) metabolic and proteomic profiles. Additionally, biophysical properties, such as deformability, were found to be changed during the infection. Based on such data, we aim to better characterize RBC functions in COVID-19. We evaluate the flow properties of RBCs in severe COVID-19 patients admitted to the intensive care unit by using in vitro microfluidic techniques and automated methods, including artificial neural networks, for an unbiased RBC analysis. We find strong flow and RBC shape impairment in COVID-19 samples and demonstrate that such changes are reversible upon suspension of COVID-19 RBCs in healthy plasma. Vice versa, healthy RBCs immediately resemble COVID-19 RBCs when suspended in COVID-19 plasma. Proteomics and metabolomics analyses allow us to detect the effect of plasma exchanges on both plasma and RBCs and demonstrate a new role of RBCs in maintaining plasma equilibria at the expense of their flow properties. Our findings provide a framework for further investigations of clinical relevance for therapies against COVID-19 and possibly other infectious diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 860436-EVIDENCE and by the Deutsche Forschungsgemeinschaft DFG in the framework of the research unit FOR 2688 "Instabilities, Bi554 furcations and Migration in Pulsatile Flows" WA 1336/13-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the Fraunhofer Institute for Translational Medicine and Pharmacology ethics committee (reference #20-643, #20-93 982).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supplementary material.